QA102 Phase 1 Study in Healthy Young and Older Adult Subjects
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This will be a double masked, randomized, placebo controlled, single and multiple oral dose
study conducted in 3 parts. The safety and tolerability of single and multiple ascending oral
doses of QA102 in healthy young and older adult subjects will be evaluated. The study will
also characterize the pharmacokinetic (PK) profile of QA102 in plasma and urine after single
and multiple oral doses of QA102. Besides, the metabolite profile of QA102 will also be
characterized.
Part 1 will comprise a single dose, sequential cohort design. Part 2 will comprise a multiple
dose, sequential cohort study. Part 3 will comprise a multiple dose, single cohort study in
older subjects.